查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2128206

2026 年至 2034 年生命科學領域生成式人工智慧的市場規模、佔有率、成長、全球產業分析、區域趨勢和預測。

Generative AI in Life Sciences Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

生命科學領域生成式人工智慧市場的成長要素

隨著製藥公司、生技公司和研究機構不斷擴大人工智慧的應用，以加速藥物研發、簡化臨床試驗、改善監管文件並提昇科學決策水平，全球生命科學領域的生成式人工智慧市場正經歷顯著成長。報告顯示，2025年全球生命科學領域生成式人工智慧市場規模為11.8億美元。預計該市場將從2026年的16億美元成長至2034年的182億美元，預測期內複合年成長率（CAGR）為35.52%。 2025年，北美市場佔據主導地位，市佔率高達46.61%，這得益於其先進的醫療基礎設施、在製藥領域強勁的研發投入以及人工智慧驅動的藥物研發平台的快速普及。

生命科學領域的生成式人工智慧包括人工智慧驅動的軟體、平台和模型，這些軟體、平台和模型支援在製藥和生物技術產業中創造科學見解、自動產生文件、最佳化分子設計以及進行數據驅動的決策。

市場定義和範圍

生成式人工智慧正在變革生命科學領域，它使機構能夠高效處理與基因組、分子、影像、監管和臨床應用相關的大量數據。這些人工智慧解決方案可協助研究人員識別候選藥物、設計臨床試驗、撰寫監管文件、總結科學文獻並改善知識管理。

該市場涵蓋軟體平台、人工智慧服務、雲端和本地部署、大規模語言模型 (LLM)、自然語言處理技術、生成式分子模型和機器學習應用。其服務對象包括製藥和生物技術公司、合約研究組織 (CRO)、研究機構、診斷公司以及其他尋求更快、更有效率研究工作流程的醫療保健機構。

市場動態

促進因素

基因組、分子和臨床數據量的不斷成長是市場擴張的主要驅動力之一。傳統分析方法往往難以處理日益複雜的資料集，而生成式人工智慧則能夠快速解讀資料、識別標靶、產生分子並最佳化臨床試驗方案。製藥公司正在採用人工智慧平台來降低研發成本、縮短研發週期並提高成功率。

趨勢

市場關鍵趨勢之一是人工智慧助理在生命科學研究領域的應用日益廣泛。這些智慧助理能夠幫助研究人員總結研究結果、比較實驗數據、撰寫報告，並從多個資料來源中提取科學洞見。企業正擴大將人工智慧助理直接整合到實驗室和研究工作流程中，從而在提高效率的同時，減輕人工文件工作的負擔。

抑制因子

監管方面的不確定性仍是限制市場成長的主要因素。醫療監管機構要求，人工智慧產生的輸出在用於科學研究或提交給監管機構之前，必須透明、檢驗、可解釋且完全可追溯。人們對人工智慧引發的「幻覺」、輸出不準確以及合規性問題的擔憂，持續限制全自動人工智慧系統的應用。

機會

生成式人工智慧在真實世界數據（RWE）和藥物安全檢測的應用日益廣泛，帶來了巨大的成長機會。人工智慧平台能夠幫助製藥公司分析病患記錄、不利事件報告和上市後監測數據，從而加快安全性監測並提高證據生成水準。

細分分析

按組件分類，軟體和平台佔據市場主導地位，這主要得益於市場對可擴展人工智慧基礎設施的需求不斷成長，這些基礎設施用於支援藥物研發、科學研究和企業知識管理。隨著各組織尋求實施、諮詢和整合方面的支持，服務領域也預計將實現強勁成長。

以部署方式來看，基於雲端的解決方案佔據了最大的市場佔有率。這是因為它們提供可擴展的計算資源、安全的協作、人工智慧模型的持續更新以及研究機構之間的輕鬆整合。

在技​​術方面，大規模語言模型（LLM）佔據市場主導地位。這是因為LLM廣泛應用於醫學寫作、監管文件編寫、文獻綜述、臨床方案製定和科學內容生成等領域。

按產品類型分類，獨立解決方案在市場上佔據主導地位，因為製藥公司更傾向於在將專用 AI 應用程式整合到其整個研究系統之前對其進行測試。

按應用領域分類，藥物發現和分子設計佔據最大佔有率，這主要得益於對人工智慧驅動的分子生成、標靶識別和生物製藥研究的大量投資。按最終用戶分類，製藥公司和生物技術公司仍然是主要採用者，它們擁有大規模部署人工智慧所需的資源和數據。

區域趨勢

預計北美將引領全球市場，到2025年市場規模將達到5.5億美元，主要得益於人工智慧的積極應用、先進的雲端基礎設施以及對藥物研發的大量投資。歐洲仍是第二大市場，這得益於負責任的人工智慧技術的日益普及以及為確保合規性所做的努力。亞太地區正在迅速崛起，這主要得益於生物技術投資的增加、製藥生產的擴張以及醫療保健數位化進程的加速。隨著醫療機構擴大採用人工智慧驅動的研究和臨床解決方案，拉丁美洲以及中東和非洲預計將保持穩定成長。

本報告對全球生命科學領域的生成式人工智慧市場進行了全面分析，包括市場規模、市場動態、成長要素、新興趨勢、市場限制、機會、組成部分、部署、技術、產品類型、應用以及2025年、2026年和2034年的最終用戶細分。報告還包括區域分析、競爭格局、公司概況以及塑造市場未來發展的最新動態。

目錄

第1章：引言

第2章執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
  • 市場趨勢

第4章：主要考慮因素

  • 技術進步概述
  • 新產品發布：按主要公司分類
  • 產業重大發展動態（合併、收購、合作、新產品和服務的推出等）
  • 按地區和國家分類的主要創業公司

第5章：2021-2034年生命科學領域全球生成式人工智慧市場分析、洞察與預測

  • 市場分析、洞察與預測：按組件分類
    • 軟體/平台
    • 服務
  • 市場分析、洞察與預測：按部署方式分類。
    • 基於雲端的
    • 現場
    • 混合
  • 市場分析、洞察與預測：按技術分類
    • 大規模語言模型（LLM）
    • 自然語言處理（NLP）
    • 生成式分子和蛋白質模型
    • 機器學習和深度學習
    • 其他
  • 市場分析、洞察與預測：按產品類型分類
    • 獨立型
    • 融合的
  • 市場分析、洞察與預測：按應用領域分類
    • 藥物發現與設計
    • 臨床試驗設計與管理
    • 準備和提交監管文件
    • 醫學事務與科學內容
    • 藥物安全監測
    • 與商業和市場進入相關的內容
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 製藥和生物技術公司
    • CRO
    • 學術和研究機構
    • 醫療技術/診斷設備公司
    • 其他
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：2021-2034年北美生命科學領域生成式人工智慧市場分析、洞察與預測

  • 國家
    • 美國
    • 加拿大

第7章：2021-2034年歐洲生命科學領域生成式人工智慧市場分析、洞察與預測

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區生命科學領域生成式人工智慧市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章：2021-2034年拉丁美洲生命科學領域生成式人工智慧市場分析、洞察與預測

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：2021-2034年中東與非洲生命科學領域生成式人工智慧市場分析、洞察與預測

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • NVIDIA Corporation
    • IQVIA Inc.
    • Oracle Corporation
    • Veeva Systems Inc.
    • Microsoft Corporation
    • Alphabet Inc.
    • Benchling, Inc.
    • Insilico Medicine
    • Recursion Pharmaceuticals, Inc.
    • Tempus AI, Inc.
Product Code: FBI117572

Growth Factors of Generative AI in Life Sciences Market

The global Generative AI in Life Sciences Market is witnessing remarkable growth as pharmaceutical companies, biotechnology firms, and research organizations increasingly adopt artificial intelligence to accelerate drug discovery, streamline clinical trials, enhance regulatory documentation, and improve scientific decision-making. According to the report, the global Generative AI in Life Sciences Market was valued at USD 1.18 billion in 2025. The market is projected to grow from USD 1.60 billion in 2026 to USD 18.20 billion by 2034, exhibiting a CAGR of 35.52% during the forecast period. In 2025, North America dominated the market with a 46.61% share, supported by advanced healthcare infrastructure, strong pharmaceutical R&D investments, and rapid adoption of AI-powered drug development platforms.

Generative AI in life sciences includes AI-powered software, platforms, and models that generate scientific insights, automate documentation, optimize molecular design, and support data-driven decision-making across the pharmaceutical and biotechnology industries.

Market Definition and Scope

Generative AI is transforming life sciences by enabling organizations to process vast volumes of genomic, molecular, imaging, regulatory, and clinical data efficiently. These AI solutions assist researchers in identifying drug candidates, designing clinical trials, generating regulatory documents, summarizing scientific literature, and improving knowledge management.

The market covers software platforms, AI services, cloud-based and on-premise deployments, large language models (LLMs), natural language processing technologies, generative molecular models, and machine learning applications. Its scope extends across pharmaceutical & biotechnology companies, contract research organizations (CROs), research institutes, diagnostics companies, and other healthcare organizations seeking faster and more efficient research workflows.

Market Dynamics

Drivers

The growing volume of genomic, molecular, and clinical data is one of the primary factors driving market expansion. Traditional analytical methods often struggle to process increasingly complex datasets, whereas generative AI enables rapid data interpretation, target identification, molecule generation, and optimized clinical trial planning. Pharmaceutical companies are adopting AI platforms to reduce development costs, accelerate research timelines, and improve success rates.

Trends

A key market trend is the rising adoption of AI copilots across life sciences research. These intelligent assistants help scientists summarize research findings, compare experimental data, generate reports, and retrieve scientific knowledge from multiple data sources. Companies are increasingly integrating AI copilots directly into laboratory and research workflows, improving productivity while reducing manual documentation efforts.

Restraints

Regulatory uncertainty remains a significant restraint for market growth. Healthcare regulators require AI-generated outputs to be transparent, validated, explainable, and fully traceable before being used in scientific or regulatory submissions. Concerns regarding AI hallucinations, inaccurate outputs, and compliance issues continue to limit the adoption of fully autonomous AI systems.

Opportunities

Growing use of generative AI in real-world evidence (RWE) and pharmacovigilance presents significant growth opportunities. AI-powered platforms help pharmaceutical companies analyze patient records, adverse event reports, and post-market surveillance data, enabling faster safety monitoring and improved evidence generation.

Segmentation Analysis

By component, software and platforms dominate the market due to increasing demand for scalable AI infrastructure supporting drug discovery, scientific research, and enterprise knowledge management. Services are expected to witness strong growth as organizations seek implementation, consulting, and integration support.

By deployment, cloud-based solutions hold the largest market share because they provide scalable computing resources, secure collaboration, continuous AI model updates, and easier integration across research organizations.

By technology, Large Language Models (LLMs) dominate the market owing to their extensive use in medical writing, regulatory documentation, literature reviews, clinical protocol development, and scientific content generation.

By product type, standalone solutions lead the market as pharmaceutical companies prefer testing dedicated AI applications before integrating them into enterprise-wide research systems.

By application, drug discovery and design account for the largest share due to heavy investments in AI-enabled molecule generation, target identification, and biologics research. By end user, pharmaceutical and biotechnology companies remain the leading adopters as they possess the resources and data necessary for large-scale AI implementation.

Regional Insights

North America leads the global market with a valuation of USD 0.55 billion in 2025, driven by strong AI adoption, advanced cloud infrastructure, and substantial pharmaceutical research investments. Europe remains the second-largest market due to increasing adoption of responsible AI technologies and regulatory compliance initiatives. Asia Pacific is emerging rapidly with growing biotechnology investments, expanding pharmaceutical manufacturing, and accelerating healthcare digitalization. Latin America and the Middle East & Africa are expected to witness steady growth as healthcare organizations increasingly adopt AI-enabled research and clinical solutions.

Competitive Landscape

The market is moderately fragmented, with leading companies focusing on AI innovation, strategic collaborations, and product development. Major players include NVIDIA Corporation, Oracle Corporation, Microsoft Corporation, IQVIA Inc., Veeva Systems Inc., Alphabet Inc., Benchling Inc., Insilico Medicine, Recursion Pharmaceuticals, and Tempus AI. These companies continue investing in scientific AI models, enterprise cloud platforms, and AI-powered drug discovery technologies to strengthen their competitive position.

Report Coverage

The report provides a comprehensive analysis of the global Generative AI in Life Sciences Market, including market size for 2025, 2026, and 2034, market dynamics, growth drivers, emerging trends, restraints, opportunities, segmentation by component, deployment, technology, product type, application, and end user. It also includes regional analysis, competitive landscape, company profiles, and recent industry developments shaping the future of the market.

Conclusion

The global Generative AI in Life Sciences Market is poised for exceptional expansion, growing from USD 1.18 billion in 2025 to USD 1.60 billion in 2026, and reaching USD 18.20 billion by 2034. Rising adoption of AI-powered drug discovery platforms, increasing pharmaceutical R&D investments, rapid digital transformation, and growing demand for efficient scientific workflows will continue driving market growth. Despite regulatory and integration challenges, continuous technological advancements and expanding AI applications across life sciences are expected to create significant long-term opportunities for market participants.

Segmentation By Component, Deployment, Technology, Product Type, Application, End User, and Region

By Component * Software/Platforms

  • Services

By Deployment * Cloud-Based

  • On-Premise
  • Hybrid

By Technology * Large Language Models (LLMs)

  • Natural Language Processing (NLP)
  • Generative Molecular/Protein Models
  • Machine Learning & Deep Learning
  • Others

By Product Type * Standalone

  • Integrated

By Application * Drug Discovery & Design

  • Clinical Trial Design & Operations
  • Regulatory Writing & Submissions
  • Medical Affairs & Scientific Content
  • Pharmacovigilance
  • Commercial & Market Access Content
  • Others

By End User * Pharmaceutical & Biotechnology Companies

  • CROs
  • Academic & Research Institutes
  • MedTech/Diagnostics Companies
  • Others

By Region * North America (By Component, Deployment, Technology, Product Type, Application, End User, and Country)

    • U.S.
    • Canada
  • Europe (By Component, Deployment, Technology, Product Type, Application, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Component, Deployment, Technology, Product Type, Application, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Component, Deployment, Technology, Product Type, Application, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Component, Deployment, Technology, Product Type, Application, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Challenges
  • 3.5. Market Trends

4. Key Insights

  • 4.1. Overview of Technological Advancements
  • 4.2. New Product Launches, By Key Players
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
  • 4.4. Key Start Ups, By Regions/Countries

5. Global Generative AI in Life Sciences Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Component
    • 5.1.1. Software/Platforms
    • 5.1.2. Services
  • 5.2. Market Analysis, Insights and Forecast - By Deployment
    • 5.2.1. Cloud-Based
    • 5.2.2. On-Premise
    • 5.2.3. Hybrid
  • 5.3. Market Analysis, Insights and Forecast - By Technology
    • 5.3.1. Large Language Models (LLMs)
    • 5.3.2. Natural Language Processing (NLP)
    • 5.3.3. Generative Molecular/Protein Models
    • 5.3.4. Machine Learning & Deep Learning
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By Product Type
    • 5.4.1. Standalone
    • 5.4.2. Integrated
  • 5.5. Market Analysis, Insights and Forecast - By Application
    • 5.5.1. Drug Discovery & Design
    • 5.5.2. Clinical Trial Design & Operations
    • 5.5.3. Regulatory Writing & Submissions
    • 5.5.4. Medical Affairs & Scientific Content
    • 5.5.5. Pharmacovigilance
    • 5.5.6. Commercial & Market Access Content
    • 5.5.7. Others
  • 5.6. Market Analysis, Insights and Forecast - By End User
    • 5.6.1. Pharmaceutical & Biotechnology Companies
    • 5.6.2. CROs
    • 5.6.3. Academic & Research Institutes
    • 5.6.4. MedTech/Diagnostics Companies
    • 5.6.5. Others
  • 5.7. Market Analysis, Insights and Forecast - Region
    • 5.7.1. North America
    • 5.7.2. Europe
    • 5.7.3. Asia Pacific
    • 5.7.4. Latin America
    • 5.7.5. Middle East & Africa

6. North America Generative AI in Life Sciences Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Component
    • 6.1.1. Software/Platforms
    • 6.1.2. Services
  • 6.2. Market Analysis, Insights and Forecast - By Deployment
    • 6.2.1. Cloud-Based
    • 6.2.2. On-Premise
    • 6.2.3. Hybrid
  • 6.3. Market Analysis, Insights and Forecast - By Technology
    • 6.3.1. Large Language Models (LLMs)
    • 6.3.2. Natural Language Processing (NLP)
    • 6.3.3. Generative Molecular/Protein Models
    • 6.3.4. Machine Learning & Deep Learning
    • 6.3.5. Others
  • 6.4. Market Analysis, Insights and Forecast - By Product Type
    • 6.4.1. Standalone
    • 6.4.2. Integrated
  • 6.5. Market Analysis, Insights and Forecast - By Application
    • 6.5.1. Drug Discovery & Design
    • 6.5.2. Clinical Trial Design & Operations
    • 6.5.3. Regulatory Writing & Submissions
    • 6.5.4. Medical Affairs & Scientific Content
    • 6.5.5. Pharmacovigilance
    • 6.5.6. Commercial & Market Access Content
    • 6.5.7. Others
  • 6.6. Market Analysis, Insights and Forecast - By End User
    • 6.6.1. Pharmaceutical & Biotechnology Companies
    • 6.6.2. CROs
    • 6.6.3. Academic & Research Institutes
    • 6.6.4. MedTech/Diagnostics Companies
    • 6.6.5. Others
  • 6.7. Market Analysis, Insights and Forecast - By Country
    • 6.7.1. U.S.
    • 6.7.2. Canada

7. Europe Generative AI in Life Sciences Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Component
    • 7.1.1. Software/Platforms
    • 7.1.2. Services
  • 7.2. Market Analysis, Insights and Forecast - By Deployment
    • 7.2.1. Cloud-Based
    • 7.2.2. On-Premise
    • 7.2.3. Hybrid
  • 7.3. Market Analysis, Insights and Forecast - By Technology
    • 7.3.1. Large Language Models (LLMs)
    • 7.3.2. Natural Language Processing (NLP)
    • 7.3.3. Generative Molecular/Protein Models
    • 7.3.4. Machine Learning & Deep Learning
    • 7.3.5. Others
  • 7.4. Market Analysis, Insights and Forecast - By Product Type
    • 7.4.1. Standalone
    • 7.4.2. Integrated
  • 7.5. Market Analysis, Insights and Forecast - By Application
    • 7.5.1. Drug Discovery & Design
    • 7.5.2. Clinical Trial Design & Operations
    • 7.5.3. Regulatory Writing & Submissions
    • 7.5.4. Medical Affairs & Scientific Content
    • 7.5.5. Pharmacovigilance
    • 7.5.6. Commercial & Market Access Content
    • 7.5.7. Others
  • 7.6. Market Analysis, Insights and Forecast - By End User
    • 7.6.1. Pharmaceutical & Biotechnology Companies
    • 7.6.2. CROs
    • 7.6.3. Academic & Research Institutes
    • 7.6.4. MedTech/Diagnostics Companies
    • 7.6.5. Others
  • 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.7.1. U.K.
    • 7.7.2. Germany
    • 7.7.3. France
    • 7.7.4. Italy
    • 7.7.5. Spain
    • 7.7.6. Scandinavia
    • 7.7.7. Rest of Europe

8. Asia Pacific Generative AI in Life Sciences Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Component
    • 8.1.1. Software/Platforms
    • 8.1.2. Services
  • 8.2. Market Analysis, Insights and Forecast - By Deployment
    • 8.2.1. Cloud-Based
    • 8.2.2. On-Premise
    • 8.2.3. Hybrid
  • 8.3. Market Analysis, Insights and Forecast - By Technology
    • 8.3.1. Large Language Models (LLMs)
    • 8.3.2. Natural Language Processing (NLP)
    • 8.3.3. Generative Molecular/Protein Models
    • 8.3.4. Machine Learning & Deep Learning
    • 8.3.5. Others
  • 8.4. Market Analysis, Insights and Forecast - By Product Type
    • 8.4.1. Standalone
    • 8.4.2. Integrated
  • 8.5. Market Analysis, Insights and Forecast - By Application
    • 8.5.1. Drug Discovery & Design
    • 8.5.2. Clinical Trial Design & Operations
    • 8.5.3. Regulatory Writing & Submissions
    • 8.5.4. Medical Affairs & Scientific Content
    • 8.5.5. Pharmacovigilance
    • 8.5.6. Commercial & Market Access Content
    • 8.5.7. Others
  • 8.6. Market Analysis, Insights and Forecast - By End User
    • 8.6.1. Pharmaceutical & Biotechnology Companies
    • 8.6.2. CROs
    • 8.6.3. Academic & Research Institutes
    • 8.6.4. MedTech/Diagnostics Companies
    • 8.6.5. Others
  • 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.7.1. China
    • 8.7.2. Japan
    • 8.7.3. India
    • 8.7.4. Southeast Asia
    • 8.7.5. Australia
    • 8.7.6. Rest of Asia Pacific

9. Latin America Generative AI in Life Sciences Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Component
    • 9.1.1. Software/Platforms
    • 9.1.2. Services
  • 9.2. Market Analysis, Insights and Forecast - By Deployment
    • 9.2.1. Cloud-Based
    • 9.2.2. On-Premise
    • 9.2.3. Hybrid
  • 9.3. Market Analysis, Insights and Forecast - By Technology
    • 9.3.1. Large Language Models (LLMs)
    • 9.3.2. Natural Language Processing (NLP)
    • 9.3.3. Generative Molecular/Protein Models
    • 9.3.4. Machine Learning & Deep Learning
    • 9.3.5. Others
  • 9.4. Market Analysis, Insights and Forecast - By Product Type
    • 9.4.1. Standalone
    • 9.4.2. Integrated
  • 9.5. Market Analysis, Insights and Forecast - By Application
    • 9.5.1. Drug Discovery & Design
    • 9.5.2. Clinical Trial Design & Operations
    • 9.5.3. Regulatory Writing & Submissions
    • 9.5.4. Medical Affairs & Scientific Content
    • 9.5.5. Pharmacovigilance
    • 9.5.6. Commercial & Market Access Content
    • 9.5.7. Others
  • 9.6. Market Analysis, Insights and Forecast - By End User
    • 9.6.1. Pharmaceutical & Biotechnology Companies
    • 9.6.2. CROs
    • 9.6.3. Academic & Research Institutes
    • 9.6.4. MedTech/Diagnostics Companies
    • 9.6.5. Others
  • 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.7.1. Brazil
    • 9.7.2. Mexico
    • 9.7.3. Rest of Latin America

10. Middle East & Africa Generative AI in Life Sciences Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Component
    • 10.1.1. Software/Platforms
    • 10.1.2. Services
  • 10.2. Market Analysis, Insights and Forecast - By Deployment
    • 10.2.1. Cloud-Based
    • 10.2.2. On-Premise
    • 10.2.3. Hybrid
  • 10.3. Market Analysis, Insights and Forecast - By Technology
    • 10.3.1. Large Language Models (LLMs)
    • 10.3.2. Natural Language Processing (NLP)
    • 10.3.3. Generative Molecular/Protein Models
    • 10.3.4. Machine Learning & Deep Learning
    • 10.3.5. Others
  • 10.4. Market Analysis, Insights and Forecast - By Product Type
    • 10.4.1. Standalone
    • 10.4.2. Integrated
  • 10.5. Market Analysis, Insights and Forecast - By Application
    • 10.5.1. Drug Discovery & Design
    • 10.5.2. Clinical Trial Design & Operations
    • 10.5.3. Regulatory Writing & Submissions
    • 10.5.4. Medical Affairs & Scientific Content
    • 10.5.5. Pharmacovigilance
    • 10.5.6. Commercial & Market Access Content
    • 10.5.7. Others
  • 10.6. Market Analysis, Insights and Forecast - By End User
    • 10.6.1. Pharmaceutical & Biotechnology Companies
    • 10.6.2. CROs
    • 10.6.3. Academic & Research Institutes
    • 10.6.4. MedTech/Diagnostics Companies
    • 10.6.5. Others
  • 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.7.1. GCC
    • 10.7.2. South Africa
    • 10.7.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. NVIDIA Corporation
    • 11.2.2. IQVIA Inc.
    • 11.2.3. Oracle Corporation
    • 11.2.4. Veeva Systems Inc.
    • 11.2.5. Microsoft Corporation
    • 11.2.6. Alphabet Inc.
    • 11.2.7. Benchling, Inc.
    • 11.2.8. Insilico Medicine
    • 11.2.9. Recursion Pharmaceuticals, Inc.
    • 11.2.10. Tempus AI, Inc.

List of Tables

  • Table 1: Global Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Component, 2021-2034
  • Table 2: Global Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Deployment, 2021-2034
  • Table 3: Global Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Technology 2021-2034
  • Table 4: Global Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 5: Global Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 6: Global Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 7: Global Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 8: North America Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Component, 2021-2034
  • Table 9: North America Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Deployment, 2021-2034
  • Table 10: North America Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Technology 2021-2034
  • Table 11: North America Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 12: North America Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 13: North America Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 14: North America Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 15: Europe Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Component, 2021-2034
  • Table 16: Europe Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Deployment, 2021-2034
  • Table 17: Europe Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Technology 2021-2034
  • Table 18: Europe Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 19: Europe Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 20: Europe Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 21: Europe Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 22: Asia Pacific Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Component, 2021-2034
  • Table 23: Asia Pacific Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Deployment, 2021-2034
  • Table 24: Asia Pacific Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Technology 2021-2034
  • Table 25: Asia Pacific Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 26: Asia Pacific Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 27: Asia Pacific Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 28: Asia Pacific Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 29: Latin America Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Component, 2021-2034
  • Table 30: Latin America Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Deployment, 2021-2034
  • Table 31: Latin America Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Technology 2021-2034
  • Table 32: Latin America Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 33: Latin America Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 34: Latin America Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 35: Latin America Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 36: Middle East & Africa Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Component, 2021-2034
  • Table 37: Middle East & Africa Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Deployment, 2021-2034
  • Table 38: Middle East & Africa Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Technology 2021-2034
  • Table 39: Middle East & Africa Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 40: Middle East & Africa Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 41: Middle East & Africa Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 42: Middle East & Africa Generative AI In Life Sciences Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Generative AI In Life Sciences Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Generative AI In Life Sciences Market Value Share (%), by Component, 2025 & 2034
  • Figure 3: Global Generative AI In Life Sciences Market Value Share (%), by Deployment, 2025 & 2034
  • Figure 4: Global Generative AI In Life Sciences Market Value Share (%), by Technology, 2025 & 2034
  • Figure 5: Global Generative AI In Life Sciences Market Value Share (%), by Product Type, 2025 & 2034
  • Figure 6: Global Generative AI In Life Sciences Market Value Share (%), by Application, 2025 & 2034
  • Figure 7: Global Generative AI In Life Sciences Market Value Share (%), by End User, 2025 & 2034
  • Figure 8: Global Generative AI In Life Sciences Market Value Share (%), by Region, 2025 & 2034
  • Figure 9: North America Generative AI In Life Sciences Market Value (USD billion), by Component, 2025 & 2034
  • Figure 10: North America Generative AI In Life Sciences Market Value Share (%), by Component, 2025
  • Figure 11: North America Generative AI In Life Sciences Market Value (USD billion), by Deployment, 2025 & 2034
  • Figure 12: North America Generative AI In Life Sciences Market Value Share (%), by Deployment, 2025
  • Figure 13: North America Generative AI In Life Sciences Market Value (USD billion), by Technology 2025 & 2034
  • Figure 14: North America Generative AI In Life Sciences Market Value Share (%), by Technology 2025
  • Figure 15: North America Generative AI In Life Sciences Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 16: North America Generative AI In Life Sciences Market Value Share (%), by Product Type, 2025
  • Figure 17: North America Generative AI In Life Sciences Market Value (USD billion), by Application, 2025 & 2034
  • Figure 18: North America Generative AI In Life Sciences Market Value Share (%), by Application, 2025
  • Figure 19: North America Generative AI In Life Sciences Market Value (USD billion), by End User, 2025 & 2034
  • Figure 20: North America Generative AI In Life Sciences Market Value Share (%), by End User, 2025
  • Figure 21: North America Generative AI In Life Sciences Market Value (USD billion), by Country, 2025 & 2034
  • Figure 22: North America Generative AI In Life Sciences Market Value Share (%), by Country, 2025
  • Figure 23: Europe Generative AI In Life Sciences Market Value (USD billion), by Component, 2025 & 2034
  • Figure 24: Europe Generative AI In Life Sciences Market Value Share (%), by Component, 2025
  • Figure 25: Europe Generative AI In Life Sciences Market Value (USD billion), by Deployment, 2025 & 2034
  • Figure 26: Europe Generative AI In Life Sciences Market Value Share (%), by Deployment, 2025
  • Figure 27: Europe Generative AI In Life Sciences Market Value (USD billion), by Technology 2025 & 2034
  • Figure 28: Europe Generative AI In Life Sciences Market Value Share (%), by Technology 2025
  • Figure 29: Europe Generative AI In Life Sciences Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 30: Europe Generative AI In Life Sciences Market Value Share (%), by Product Type, 2025
  • Figure 31: Europe Generative AI In Life Sciences Market Value (USD billion), by Application, 2025 & 2034
  • Figure 32: Europe Generative AI In Life Sciences Market Value Share (%), by Application, 2025
  • Figure 33: Europe Generative AI In Life Sciences Market Value (USD billion), by End User, 2025 & 2034
  • Figure 34: Europe Generative AI In Life Sciences Market Value Share (%), by End User, 2025
  • Figure 35: Europe Generative AI In Life Sciences Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 36: Europe Generative AI In Life Sciences Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 37: Asia Pacific Generative AI In Life Sciences Market Value (USD billion), by Component, 2025 & 2034
  • Figure 38: Asia Pacific Generative AI In Life Sciences Market Value Share (%), by Component, 2025
  • Figure 39: Asia Pacific Generative AI In Life Sciences Market Value (USD billion), by Deployment, 2025 & 2034
  • Figure 40: Asia Pacific Generative AI In Life Sciences Market Value Share (%), by Deployment, 2025
  • Figure 41: Asia Pacific Generative AI In Life Sciences Market Value (USD billion), by Technology 2025 & 2034
  • Figure 42: Asia Pacific Generative AI In Life Sciences Market Value Share (%), by Technology 2025
  • Figure 43: Asia Pacific Generative AI In Life Sciences Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 44: Asia Pacific Generative AI In Life Sciences Market Value Share (%), by Product Type, 2025
  • Figure 45: Asia Pacific Generative AI In Life Sciences Market Value (USD billion), by Application, 2025 & 2034
  • Figure 46: Asia Pacific Generative AI In Life Sciences Market Value Share (%), by Application, 2025
  • Figure 47: Asia Pacific Generative AI In Life Sciences Market Value (USD billion), by End User, 2025 & 2034
  • Figure 48: Asia Pacific Generative AI In Life Sciences Market Value Share (%), by End User, 2025
  • Figure 49: Asia Pacific Generative AI In Life Sciences Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 50: Asia Pacific Generative AI In Life Sciences Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 51: Latin America Generative AI In Life Sciences Market Value (USD billion), by Component, 2025 & 2034
  • Figure 52: Latin America Generative AI In Life Sciences Market Value Share (%), by Component, 2025
  • Figure 53: Latin America Generative AI In Life Sciences Market Value (USD billion), by Deployment, 2025 & 2034
  • Figure 54: Latin America Generative AI In Life Sciences Market Value Share (%), by Deployment, 2025
  • Figure 55: Latin America Generative AI In Life Sciences Market Value (USD billion), by Technology 2025 & 2034
  • Figure 56: Latin America Generative AI In Life Sciences Market Value Share (%), by Technology 2025
  • Figure 57: Latin America Generative AI In Life Sciences Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 58: Latin America Generative AI In Life Sciences Market Value Share (%), by Product Type, 2025
  • Figure 59: Latin America Generative AI In Life Sciences Market Value (USD billion), by Application, 2025 & 2034
  • Figure 60: Latin America Generative AI In Life Sciences Market Value Share (%), by Application, 2025
  • Figure 61: Latin America Generative AI In Life Sciences Market Value (USD billion), by End User, 2025 & 2034
  • Figure 62: Latin America Generative AI In Life Sciences Market Value Share (%), by End User, 2025
  • Figure 63: Latin America Generative AI In Life Sciences Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 64: Latin America Generative AI In Life Sciences Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 65: Middle East & Africa Generative AI In Life Sciences Market Value (USD billion), by Component, 2025 & 2034
  • Figure 66: Middle East & Africa Generative AI In Life Sciences Market Value Share (%), by Component, 2025
  • Figure 67: Middle East & Africa Generative AI In Life Sciences Market Value (USD billion), by Deployment, 2025 & 2034
  • Figure 68: Middle East & Africa Generative AI In Life Sciences Market Value Share (%), by Deployment, 2025
  • Figure 69: Middle East & Africa Generative AI In Life Sciences Market Value (USD billion), by Technology 2025 & 2034
  • Figure 70: Middle East & Africa Generative AI In Life Sciences Market Value Share (%), by Technology 2025
  • Figure 71: Middle East & Africa Generative AI In Life Sciences Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 72: Middle East & Africa Generative AI In Life Sciences Market Value Share (%), by Product Type, 2025
  • Figure 73: Middle East & Africa Generative AI In Life Sciences Market Value (USD billion), by Application, 2025 & 2034
  • Figure 74: Middle East & Africa Generative AI In Life Sciences Market Value Share (%), by Application, 2025
  • Figure 75: Middle East & Africa Generative AI In Life Sciences Market Value (USD billion), by End User, 2025 & 2034
  • Figure 76: Middle East & Africa Generative AI In Life Sciences Market Value Share (%), by End User, 2025
  • Figure 77: Middle East & Africa Generative AI In Life Sciences Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 78: Middle East & Africa Generative AI In Life Sciences Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 79: Global Generative AI In Life Sciences Market Share (%), by Company, 2025